Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.64 |
| ▸ | KLK7 | P49862 | 4/20 | 0.64 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2840917 | 0.90 | KLK5 (0.59) | KLK5KLK7ITGB3ITGA2BMAPT | |
| SCHEMBL29551992 | 0.87 | KLK7 (0.61) | KLK5KLK7ITGB3ITGA2BMAPT | |
| SCHEMBL2842784 | 0.83 | SIRT5 (0.47) | KLK5KLK7CASP3CTSK | |
| SCHEMBL2849324 | 0.82 | PTGER4 (0.47) | KLK5KLK7CASP3 | |
| SCHEMBL16798514 | 0.82 | MAPT (0.61) | KLK5KLK7ITGB3ITGA2BMAPT | |
| SCHEMBL16798512 | 0.82 | MAPT (0.61) | KLK5KLK7ITGB3ITGA2BMAPT | |
| SCHEMBL2844570 | 0.82 | ANPEP (0.53) | CASP3CTSK | |
| SCHEMBL16124431 | 0.81 | MAPT (0.60) | KLK5KLK7ITGB3ITGA2BMAPT | |
| SCHEMBL31250936 | 0.81 | KLK7 (0.58) | KLK5KLK7ITGB3ITGA2BMAPT | |
| SCHEMBL1374913 | 0.81 | MAPT (0.64) | KLK5KLK7ITGB3ITGA2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216803-A1 | ORNITHINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-2141147-A1 | ORNITHINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216803-A1 | ORNITHINE DERIVATIVE | PTGER4, OXER1, ODC1 | KLK5 1391/4885KLK7 2470/4885ITGB3 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.